Fulcrum Therapeutics (FULC) AI Stock Analysis

• Market Cap: $378.10M
• Dividend Yield: N/A
• Average Volume (3M): 497.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: -100.00%
• EPS Growth: -266.37%
• Country: US
• Employees: 45
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 54,091,587
• 10 Day Avg. Volume: 367,030
• 30 Day Avg. Volume: 497,663
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -2.74
• 1Y Price Target: $10.57
• Price Target Upside: 51.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 56 Neutral
• Price Target: $7.00 ▲(0.00% Upside)

Fulcrum Therapeutics' overall score is driven by its strong corporate events and robust balance sheet, offset by challenges in profitability and valuation. The company's strategic advancements in sickle cell treatment are promising, but financial sustainability remains a concern.

Positive Factors

Strategic Focus on Rare Diseases

Fulcrum's strategic focus on genetically defined rare diseases, such as sickle cell disease, positions it as a key player in addressing unmet medical needs, potentially leading to significant market opportunities and long-term growth.

Robust Balance Sheet

A strong balance sheet with minimal debt provides Fulcrum with financial stability and flexibility to invest in R&D and strategic initiatives, supporting long-term business sustainability.

Promising Clinical Trial Results

Positive clinical trial results for pociredir in treating sickle cell disease enhance Fulcrum's competitive edge in the biopharmaceutical industry, potentially leading to successful product commercialization and revenue growth.

Negative Factors

Operational Profitability Challenges

Persistent operational losses and negative EBIT margin highlight challenges in achieving profitability, which could impact Fulcrum's ability to sustain long-term operations without additional funding.

Cash Flow Sustainability Concerns

Despite recent improvements, the unsustainable cash flow to net income ratio suggests potential difficulties in maintaining positive cash flow, which could limit Fulcrum's ability to fund future growth initiatives.

Revenue Growth Decline

A significant decline in revenue growth indicates challenges in expanding market presence and generating sales, potentially affecting Fulcrum's long-term financial performance and market competitiveness.

Fulcrum Therapeutics Business Overview & Revenue Model

Company Description

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat genetic diseases. Operating within the biotechnology sector, the company specializes in small molecule therapeutics aimed at modulating gene expression and addressing the underlying causes of various neuromuscular and other rare diseases. Its lead product candidates include treatments for conditions like Duchenne Muscular Dystrophy (DMD) and other related disorders, leveraging advanced scientific research and development to improve patient outcomes.

How the Company Makes Money

Fulcrum Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn money through various channels, including partnerships with larger pharmaceutical companies that provide funding for research and development in exchange for a share in future profits. Additionally, Fulcrum can benefit from milestones and royalties associated with the successful advancement of its drug candidates through clinical trials and regulatory approvals. Other potential revenue sources include licensing agreements for its proprietary technologies and intellectual property, as well as government grants and research funding aimed at supporting innovative therapeutic research.

Fulcrum Therapeutics Financial Statement Overview

Summary

Fulcrum Therapeutics has a strong gross profit margin and a robust balance sheet with low leverage. However, the company faces challenges with operational profitability and cash flow sustainability due to consistent net losses.

Income Statement

Fulcrum Therapeutics shows a stable revenue over the TTM period with $80M, but the company is struggling with negative net income at -$510,000 and a significant negative EBIT margin of -15.58%. The company's gross profit margin is strong at 78.42%, indicating good cost control over production, but the high operating losses need addressing to improve profitability.

Balance Sheet

The balance sheet of Fulcrum Therapeutics is robust, with a high equity ratio of 94.15% and low debt-to-equity ratio of 0.04, indicating minimal reliance on debt. The company's stockholders' equity stands strong at $228.49M, providing a solid financial foundation. However, the company needs to focus on converting this equity strength into operational profitability.

Cash Flow

Fulcrum Therapeutics shows improvement in cash flow with a positive operating cash flow of $7.81M in the TTM period, turning around from previous negative cash flows. The free cash flow is also positive at $7.56M, indicating better cash management. However, the operating cash flow to net income ratio is not sustainable at 15.31 due to negative net income, which suggests future cash flow stability is uncertain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	80.00M	2.81M	6.34M	19.16M	8.82M
Gross Profit	0.00	78.41M	2.81M	3.93M	16.65M	6.44M
EBITDA	-81.62M	-18.24M	-108.49M	-109.72M	-78.54M	-69.23M
Net Income	-73.22M	-9.72M	-97.33M	-105.62M	-78.33M	-68.44M
Balance Sheet
Total Assets	228.84M	260.72M	257.69M	226.69M	235.00M	129.58M
Cash, Cash Equivalents and Short-Term Investments	214.11M	241.02M	236.22M	202.92M	218.16M	112.91M
Total Debt	7.57M	8.63M	10.82M	13.42M	0.00	17.00K
Total Liabilities	14.46M	17.68M	22.50M	27.74M	23.46M	34.40M
Stockholders Equity	214.38M	243.03M	235.19M	198.94M	211.54M	95.18M
Cash Flow
Free Cash Flow	-65.22M	-2.50M	-91.47M	-99.01M	-80.19M	-55.00M
Operating Cash Flow	-64.91M	-2.22M	-90.97M	-97.05M	-78.48M	-53.66M
Investing Cash Flow	19.77M	32.23M	-36.69M	12.41M	-129.67M	-57.14M
Financing Cash Flow	1.02M	2.75M	118.12M	84.32M	186.51M	71.13M

Fulcrum Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FULC, the sentiment is Positive. The current price of 7 is above the 20-day moving average (MA) of 6.78, below the 50-day MA of 7.09, and above the 200-day MA of 5.14, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 52.07 is Neutral, neither overbought nor oversold. The STOCH value of 42.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FULC.

Fulcrum Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PBYI	69 Neutral	$226.67M	4.56	63.24%	―	8.63%	429.84%
FULC	56 Neutral	$378.10M	―	-30.00%	―	-100.00%	-266.37%
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
TNGX	47 Neutral	$761.02M	―	-76.09%	―	-42.84%	-17.32%
DSGN	47 Neutral	$339.41M	―	-26.77%	―	―	-24.60%
IKT	46 Neutral	$125.19M	―	-97.49%	―	-100.00%	62.82%
DMAC	42 Neutral	$376.30M	―	-73.41%	―	―	-31.78%

Fulcrum Therapeutics Corporate Events

Fulcrum Therapeutics Highlights Progress in Sickle Cell Treatment

On August 28, 2025, Fulcrum Therapeutics released an updated corporate presentation highlighting their progress and strategic focus on developing treatments for genetically defined rare diseases. The presentation emphasized the potential of pociredir in treating sickle cell disease, showcasing promising results from their Phase 1b PIONEER study, which demonstrated significant increases in fetal hemoglobin and improvements in key markers of hemolysis. These developments position Fulcrum as a key player in addressing the unmet needs in the SCD treatment landscape, despite recent challenges faced by other therapies in the market.

Fulcrum Therapeutics Announces Promising Phase 1b Trial Results

On July 29, 2025, Fulcrum Therapeutics announced promising results from the 12 mg dose cohort of its Phase 1b clinical trial of pociredir for sickle cell disease. The trial showed significant increases in fetal hemoglobin and improvements in key markers of hemolysis and anemia, with pociredir being well-tolerated and no serious adverse events reported. These findings suggest potential benefits in reducing vaso-occlusive crises and improving patient outcomes, positioning Fulcrum favorably in the biopharmaceutical industry. The company also reported a cash runway into 2028, despite a net loss in the second quarter of 2025.

Fulcrum Therapeutics Elects New Directors at Annual Meeting

At the 2025 annual meeting held on June 26, Fulcrum Therapeutics‘ stockholders elected Katina Dorton, Robert Gould, and Kate Haviland as class III directors for a three-year term. Additionally, stockholders approved the compensation of the company’s named executive officers and decided on an annual frequency for future advisory votes on this matter. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions underscore Fulcrum’s commitment to maintaining strong governance and financial oversight, potentially enhancing stakeholder confidence.